EMERGENCY: Coronavirus disease (COVID-19) Pandemic16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.
New publication: The European response to the WHO call to eliminate cervical cancer as a public health problem08/07/2020
This reports addresses for the first time the question how Europe could answer to the ambitious call from the World Health Organisation to reduce the incidence of cervical cancer to less than 4/100 000/year by reaching, by the 2030 >90, 70 and 90% coverage for HPV vaccination, HPV-based screening and management of screen-positive women, respectively. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. The authors of this paper underline the need for a new third edition of EU guidelines for integrated primary and secondary prevention of cervical cancer. View the article.
New publication: Human papillomavirus vaccination: Good clinical practice recommendations from the Federation of Obstetric and Gynecological Societies of India06/07/2020
The Federation of Obstetric and Gynecological Societies of India (FOGSI) convened an expert group on cervical cancer prevention to formulate good clinical practice recommendations (GCPR) with respect to vaccine efficacy and safety, target groups, optimal timing and dosing schedules. Experts concluded that HPV vaccination should be the priority to achieve the elimination of cervical cancer. The introduction of affordable HPV vaccines and reduced dose schedules will improve coverage. View the publication.
New commentary: Two-dose recommendation up to 18 years11/06/2020
In this commentary published in HPVWORLD, Dr Partha Basu and colleagues demonstrate that protection against the vaccine-targeted HPV types (HPV16 and 18) or the cross-protective types (HPV31, 33 and 45) is similar in the 15-18 year-old women irrespective of whether they received two doses or three doses.
View the commentary.
New publication: Correlation Between p16/Ki-67 Expression and the Grade of Cervical Intraepithelial Neoplasias.10/06/2020
This article published in the International Journal of Gynecological Pathology reports the evaluation of the biomarkers p16 and Ki-67 in improving the diagnostic accuracy of cervical histopathology and assess the correlation between p16 expression and human papillomavirus test in different grades of cervical intraepithelial neoplasia (CIN). Authors concluded that dual staining could be used as an adjunctive test to improve the diagnostic accuracy of histopathology. In addition, p16/Ki-67 IHC has a role in guiding management decisions in cases with discordant colposcopy and histopathology diagnoses. View the article.
New commentary: Single-dose efficacy of bivalent HPV vaccine09/06/2020
In this commentary published in HPVWORLD, Dr Partha Basu and colleagues share the preliminary findings suggesting high vaccine effectiveness in preventing incident HPV16/18 infections, as well as persistent infections, regardless of the number of doses received.
View the commentary.
New publication: A Prospective Randomized Trial to Compare Safety, Acceptability and Efficacy of Thermal Ablation and Cryotherapy in a Screen and Treat Setting.28/05/2020
Authors report the results of a prospective randomized study conducted at Chittaranjan National Cancer Institute (CNCI), Kolkata, India, comparing the safety, acceptability and efficacy of thermal ablation with cryotherapy in a screen and treat setting. Authors conclude that thermal ablation is as acceptable and safe as cryotherapy. Thermal ablation has the logistic advantages for the low-resourced settings as the machines are more portable, do not require costly refrigerant gas and battery-driven models are available. View the article.
New publication: Multicentric Study of Cervical Cancer Screening With Human Papillomavirus Testing and Assessment of Triage Methods in Latin America: The ESTAMPA Screening Study Protocol25/05/2020
This article published in BMJ Open, describes the protocol of the largest cervical screening study (ESTAMPA) implemented in Latin America, across 12 study centres. The ESTAMPA study objectives are to evaluate the performance of different triage techniques to detect cervical precancer and to inform on how to implement HPV-based screening programmes in LMIC. This study will permit evaluation of several triage tests, alone or in combination, for HPV-positive women. View the article.
New commentary: The Quebec mixed-schedule HPV vaccination policy will maximize public health gain18/05/2020
In this commentary published in HPVWORLD, Dr Partha Basu discusses the Quebec's Mixed HPV vaccination schedule introduction.
View the commentary.
New publication: Feasibility, Acceptability, and Efficacy of a Community Health Worker-Driven Approach to Screen Hard-to-Reach Periurban Women Using Self-Sampled HPV Detection Test in India29/04/2020
This article published in JCO Global Oncology reports the evaluation of the feasibility, acceptability, and efficacy of implementing an HPV self-sampling–based approach to screen a socioeconomically disadvantaged, unscreened population with support from community health workers (CHWs). Authors concluded CHW-driven self-sampling for HPV testing is feasible, well-accepted, and effective for screening unscreened hard-to-reach women. The screen-and-treat approach can ensure linkage between screening and treatment. View the article.